Captrust Financial Advisors Has $163.09 Million Stock Holdings in Amgen Inc. $AMGN

Captrust Financial Advisors lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 498,265 shares of the medical research company’s stock after buying an additional 12,562 shares during the period. Captrust Financial Advisors owned about 0.09% of Amgen worth $163,087,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in Amgen during the fourth quarter valued at $26,000. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new stake in Amgen during the fourth quarter valued at $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Trading Down 0.8%

Amgen stock opened at $347.84 on Wednesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The business’s 50-day simple moving average is $341.02 and its 200-day simple moving average is $345.89. The firm has a market capitalization of $187.73 billion, a PE ratio of 24.21, a PEG ratio of 3.52 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Daiwa Securities Group reduced their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Barclays assumed coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research report on Friday, June 5th. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Leerink Partners reissued a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.